Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.56 |
| ▸ | HRH1 | P35367 | 13/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.56 |
| ▸ | HTR1E | P28566 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813204 | 1.00 | HTR6 (0.56) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL2816894 | 1.00 | HTR6 (0.56) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| Hydrochloric Acid SCHEMBL2811886 | 0.99 | HTR6 (0.55) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL2815305 | 0.95 | HRH1 (0.55) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL2813870 | 0.95 | HRH1 (0.55) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL2815551 | 0.95 | HRH1 (0.55) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL15290460 | 0.94 | HTR6 (0.49) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL2814641 | 0.90 | HTR6 (0.45) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL2814191 | 0.90 | HRH1 (0.45) | HTR6HRH1SIGMAR1ADRA2AHTR2A | |
| SCHEMBL13394750 | 0.90 | HTR6 (0.45) | HTR6HRH1SIGMAR1ADRA2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | claimed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | claimed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | claimed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | claimed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2274307-B1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9051314-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20130190303-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2009120720-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES,INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HTR6 21/4885HRH1 457/4885SIGMAR1 556/4885 |
| US-20130184269-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | HTR6 22/4885HRH1 10/4885SIGMAR1 275/4885 |
| US-20130190303-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | HTR6 22/4885HRH1 10/4885SIGMAR1 275/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HTR6 21/4885HRH1 457/4885SIGMAR1 556/4885 |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | HTR6 22/4885HRH1 10/4885SIGMAR1 275/4885 |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HTR6 21/4885HRH1 457/4885SIGMAR1 556/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | HTR6 21/4885HRH1 457/4885SIGMAR1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.